# Apixaban Versus Warfarin for Left Ventricular Thrombus

Study · id `cardio:ct-nct07709780` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07709780](<https://clinicaltrials.gov/study/NCT07709780>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07709780

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 218 participants.

## Technical summary

Registry record NCT07709780. Randomized; no masking; primary purpose treatment. Start 2026-06-22 (anticipated); primary completion 2028-07-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 218 participants (planned count; ClinicalTrials.gov record NCT07709780, source copy `cardio:ctgov-nct07709780-2026-07-17`, retrieved 2026-10-26)
- Planned start: 2026-06-22 (anticipated) (ClinicalTrials.gov record NCT07709780, source copy `cardio:ctgov-nct07709780-2026-07-17`, retrieved 2026-10-26)
- Primary completion: 2028-07-01 (anticipated) (ClinicalTrials.gov record NCT07709780, source copy `cardio:ctgov-nct07709780-2026-07-17`, retrieved 2026-10-26)
- Completion: 2029-07-01 (anticipated) (ClinicalTrials.gov record NCT07709780, source copy `cardio:ctgov-nct07709780-2026-07-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07709780, source copy `cardio:ctgov-nct07709780-2026-07-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07709780-2026-07-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Apixaban Versus Warfarin for Left Ventricular Thrombus
- Acronym: APEX
- Condition: Left Ventricular Thrombus
- Intervention (Drug): Apixaban
- Intervention (Drug): Warfarin
- Lead sponsor: University of Arizona
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: University of Arizona (`cardio:org-university-of-arizona`)

## Provenance

Content hash: 9ec7e029943ef43ab79de008886d93b63cdab385b27b11345aefb03e6b6194d7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
